111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
暂无分享,去创建一个
E. D. de Vries | T. Suter | J. Gietema | W. T. van der Graaf | D. V. van Veldhuisen | W. Sluiter | M. L. Lub-de Hooge | M. A. D. Korte | P. Perik | P. Jager | M. D. de Korte | D. Sleijfer | W. V. D. van der Graaf | J. A. Gietema | M. D. Hooge | D. J. V. Veldhuisen | Thomas M. Suter | E. D. Vries | W. Sluiter | D. Sleijfer | W. T. A. Graaf | P. L. Jager
[1] E. D. de Vries,et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Chien. Herceptin and the heart--a molecular modifier of cardiac failure. , 2006, The New England journal of medicine.
[3] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[4] V. Valero,et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[7] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[8] S. Lippman,et al. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. LeBrasseur,et al. Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1β/erbB4 Signaling* , 2004, Journal of Biological Chemistry.
[10] J. Bart,et al. Preclinical characterisation of 111In‐DTPA‐trastuzumab , 2004, British journal of pharmacology.
[11] W. Lichtenegger,et al. Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™) , 2003, Breast Cancer Research and Treatment.
[12] O. Frazier,et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[14] Susumu Minamisawa,et al. ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.
[15] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[16] P. Singal,et al. Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.